Skip to content
  • About us
    • Overview
    • Our founders
    • Careers
  • Our pipeline
    • Development pipeline
    • Netazepide
      • Background
      • Studies
      • Further studies
    • Ceclazepide
    • TR4
    • TR8
  • Trio Medicines Logo
  • Our publications
  • Contact us

Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.

myarzi12019-03-26T13:15:19+00:00Uncategorized|
Read More

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.

myarzi12019-03-26T13:20:58+00:00Uncategorized|
Read More